A study published by Imperial College of Science and Technology showed that researchers used a cancer treatment drug to treat pulmonary hypertension based on precision medical technology. Early clinical trials worked well. If further trials are successful, it is expected that in the future, tailor-made effective therapies will be developed for patients with this condition. Pulmonary hypertension refers to a hemodynamic and pathophysiological state in which pulmonary arterial pressure rises above a certain threshold. If left untreated, patients usually die of heart failure several years later. A team led by researchers from Imperial College and the University of Alberta in Canada conducted an in-depth study of pulmonary hypertension. They analyzed the condition of 20 patients and samples of lung tissue from patients. In general, mitochondrial function in patients with pulmonary hypertension is disordered. According to the report published in the journal Science Translational Medicine, the team found that the lungs of this type of patient have a higher enzyme content called PDK than normal people and are more active in mitochondria. Further clinical trials have shown that the drug dichloroacetate, which was previously used primarily for the experimental treatment of brain tumors, can accurately target this enzyme and prevent it from functioning, thereby enhancing the function of the mitochondria and lowering the blood pressure of the patient's lungs. . But the team also pointed out that not all patients respond to this treatment, which is related to the variation of related genes in some patients. Martin Wilkins, one of the authors of the report and imperial professor of Imperial College, said that this is a good example of precision medicine . The genes of the patients themselves can be used to predict whether a drug is effective, by focusing on those who are able to Patients who respond will enable clinical trials to be carried out more efficiently and at lower cost in the future. The next phase of the team will conduct clinical trials for patients who are genetically responsive to dichloroacetate in order to develop more targeted new therapies for such patients. (Xinhua) Anti oxidation, has the function of delaying aging and resisting fatigue, Astaxanthin can significantly reduce the ROS and NMP on the dermal layer of collagen, elastin damage, to ensure the normal metabolism of the skin, Ginkgo biloba extract can directly eliminate lipid free radicals, lipid peroxidation free radicals and alkyl radicals, and terminate the free radical chain reaction chain.Panax ginseng can be formulated into freckle, reduce wrinkles, activate skin cells, enhance skin elasticity of cosmetics. Health Care Antioxidant Supplement,Health Antioxidant Ingredients,Healthcare Antioxidant Raw Material,Health Care Xi'an Natural Field Bio-Technique Co., Ltd. , https://www.naturalnf.com